Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

A genetically engineered pig kidney helped Towana Looney enjoy 130 days without the need for dialysis before the organ was ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company’s revenue is heavily ...

On Monday, BofA Securities analyst Greg Harrison upgraded United Therapeutics Corporation (NASDAQ:UTHR) from Underperform to Neutral, setting a price target of $314.00 for the company’s shares.

Presented by Andrew Stine, United Therapeutics. Poster Session 1. Cardiology, Sunday, April 27, 6:00 – 7:00 p.m. ET: 447 – Clinical Correlations with Cardiac Power Output-to-Mass and Left ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that ...